 |
 |
I am making a presentation to my PD support group regarding drug pricing. One of my areas of work relates to issues of social responsibility of corporations. A few years ago I gathered lots of info on the pricing of eldepryl. At the time there were congressional hearings on drug pricing and I received some excellent info from aides to congress people following the issue. I still have my files that cover issues like falsified drug tests, corporate lobbying, intellectual property. Most is dated, but still interesting. I would appreciate information in this area. Some areas and questions that might help to focus my research: Names of pharmaceutical companies and their parent companies or corporate partners involved in research, development and sale of PD drugs; present status of congressional activity on drug pricing; any recent reprints, e.g., from Government Printing Office, on drug pricing; any comparisons of drug pricing of the main PD drugs, for instance, local retail versus mail-order, various price lists used for hospitals, large buyers like VA, small retail pharmacists; any info (almost impossible to obtain) on pharmaceutical company lobbying; is there info on numbers of people with PD who cannot obtain necessary drugs; given the large percentage of the population unable to pay for health insurance I would think this could be a good number; a social worker said this group would be almost impossible to track because they would fall outside of any private or government program. Thanks for whatever help. I will be glad to share info on this topic. Pat McManamon [log in to unmask] 438 St. Antoine Detroit, MI 48226 313-961-8078 or 961-2145 313-963-5134 fax